BACKGROUND: There are contrasting reports on the effectiveness of a concomitant intra-aortic balloon pump (IABP) in cardiogenic shock patients treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO). This study sought to compare short-term mortality in patients with cardiogenic shock treated with VA-ECMO with and without IABP.
C
ardiogenic shock is a leading cause of mortality and morbidity in acute cardiovascular care and is associated with short-term mortality of nearly 30% to 45% in the contemporary era. 1, 2 Traditionally, these patients were conservatively managed using high-dose vasoactive medications and an intra-aortic balloon pump (IABP) for hemodynamic support. 2, 3 The use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has caused a paradigm shift in management during the past decade. 4, 5 In patients with cardiogenic shock, both oxygen supply and perfusion are critically impaired making this an attractive choice of mechanical circulatory support (MCS) in this population as compared to others devices. 6 A potential downside of peripheral VA-ECMO is the retrograde aortic flow which results in increased left ventricular (LV) afterload and further compromises LV efficiency. 7 This increased LV afterload can result in an increased LV chamber size with a consequent increase in left atrial pressure and pulmonary edema. 7 Moreover, the increase in LV stress may exacerbate myocardial ischemia and contribute to worsening cardiogenic shock. As a consequence, a logical approach which has been widely used is to decompress the LV using non-MCS techniques or concomitant use of MCS devices, such as the Impella, TandemHeart, and IABP. 7 The role of the IABP in providing additional circulatory support and LV decompression in patients with concomitant VA-ECMO is controversial. [7] [8] [9] In light of the multiple recent studies demonstrating contrasting results, we sought to systematically review the available evidence of the role of concomitant IABP on short-term mortality outcomes in patients with cardiogenic shock necessitating VA-ECMO support. Our primary hypothesis was that use of a concomitant IABP is associated with decreased short-term mortality in cardiogenic shock patients on VA-ECMO.
MATERIAL AND METHODS

Data Sources and Search Strategies
A comprehensive search of several databases from January 1, 2000 to February 9, 2018, was conducted. The databases included Ovid MEDLINE Epub Ahead of Print, Ovid Medline In-Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus. The search strategy was designed and conducted by a medical librarian with input from the study's first author. Controlled vocabulary supplemented with keywords was used to search for mortality outcomes in cardiogenic shock needing VA-ECMO with the concomitant use of IABP in adults. The detailed search strategy is presented in Appendix I in the Data Supplement. The resultant abstracts were screened by 2 independent reviewers (S. Ananthaneni, P. Antharam). All references of included studies were evaluated for additional studies. Study inclusion was based on the consensus of the 2 reviewers. A third independent reviewer (Saarwaani Vallabhajosyula) served as the referee in case of disagreement between the first 2 reviewers. The search strategy and reporting were performed using STROBE guidelines (Strengthening the Reporting of Observational Studies in Epidemiology). 10 Institutional review board approval was not sought because of the use of publicly available cumulative published data. The data, analytic methods, and study materials are readily available to other researchers for purposes of reproducing the results or replicating the procedure given the publicly available cumulative published data.
Inclusion and Exclusion Criteria
Studies that reported on short-term mortality in ≥10 adult (>18 years) patients with cardiogenic shock necessitating VA-ECMO were included. The primary outcome was shortterm mortality defined as mortality during intensive care unit or hospital stay and mortality ≤30 days. Literature from human studies and of case-control, cohort, case series, and randomized trial study designs were included. In studies reporting outcomes in unselected shock patients, only studies for which a 2×2 table could be constructed between IABP use and mortality were included. Abstracts presented at professional societal meetings were excluded because they are subject to a higher risk of bias from lack of rigorous peer review. Studies designed as case reports, systematic or narrative reviews, pediatric or animal studies, and studies without relevant outcomes were excluded. If multiple studies were published by the same group of authors for the same study duration, the most comprehensive study with relevant outcomes was included. Data abstracted included study year, population, location, type of study, MCS-related parameters, and clinical outcomes. Quality was assessed using the
WHAT IS KNOWN
• Use of veno-arterial extracorporeal membrane oxygenation may be associated with left ventricular distension, poor myocardial perfusion, and hydrostatic pulmonary edema.
• Left ventricular unloading using surgical or percutaneous devices may be needed to optimize left ventricular function and mechanics in these patients.
• There are contrasting reports on the role of a concomitant intra-aortic balloon pump in patients with cardiogenic shock on veno-arterial extracorporeal membrane oxygenation.
WHAT THIS STUDY ADDS
• In patients with cardiogenic shock needing venoarterial extracorporeal membrane oxygenation support, use of a concomitant intra-aortic balloon pump did not demonstrate any differences in short-term mortality.
• In patients with cardiogenic shock complicating acute myocardial infarction, the use of an intraaortic balloon pump with veno-arterial extracorporeal membrane oxygenation was associated with lower mortality.
Newcastle Ottawa Scale (http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp).
Statistical Analysis
Heterogeneity among the studies was estimated using the I 2 statistic as described by Higgins et al. 11 I 2 values of <50%, 50% to 75%, and >75% are deemed to have low, moderate, and high heterogeneity, respectively. A Mantel-Haenszel model was used to calculate pooled risk ratios (RR) and 95% CI. Further random-or fixed-effects models were chosen based on heterogeneity; a random-effects model was selected when the I 2 was > 50%. Publication bias was estimated by visual inspection of funnel plots for asymmetry. Exclusion sensitivity analysis was performed to assess the impact of individual studies. An apriori stratified analysis by cause of cardiogenic shock (acute myocardial infarction [AMI], postcardiotomy cardiogenic shock and mixed/other causes) was performed to explore heterogeneity. Study results were considered statistically significant when the CI range did not include unity, and the P-value was <0.05. Statistical analysis was performed using Comprehensive Meta-Analysis Version 2.0 (Biostat, Inc, Englewood, NJ).
RESULTS
The search strategy identified 639 abstracts, of which 22 studies, representing 4653 patients met the inclusion criteria ( Figure 1 and Tables 1 and 2) . 9, All studies except the study by Beurtheret et al 26 were retrospective cohort studies. In total, 2596 (55.8%) were treated with only VA-ECMO and 2057 (44.2%) with both VA-ECMO and IABP. Peripheral VA-ECMO was used in a majority of the patients in the studies (Table 3) . Cardiogenic shock definition was specified in only 13 (59%) studies and was defined using a combination of blood pressure targets (systolic <70-90 mm Hg; mean <60-65 mm Hg), end-organ injury, increasing or maximal doses of inotropes and vasopressors, refractory malignant arrhythmias, and cardiac arrest with cardiopulmonary resuscitation. Severe or irreversible neurological disease, but not mildmoderate neurological impairment, remained a common exclusion criteria with other criteria varying based on the population studied (Table 1) . Baseline LV ejection fractions between the 2 cohorts were provided only in 2 studies. In the studies by Bréchot et al 27 Tables 2 and 3 .
In the pooled analysis, short-term mortality was not significantly different in cardiogenic shock patients on VA-ECMO with and without IABP 42.1% versus 57.8%; RR, 0.80; 95% CI, 0.52-1.22; P=0.30 ( Figure 2 ). Heterogeneity between studies was high between studies (I 2 =81%), and funnel plot suggested possible publication bias ( Figure 3 ). To explore heterogeneity and publication bias, a number of sensitivity analyses were performed. Individually removing and readding large studies, Aso et al, 9 Lin et al, 28 Papadopoulos et al, 21 or Rastan et al, 22 and studies that were outliers on the funnel plot did not influence the overall RRs. When stratified by cause of cardiogenic shock, heterogeneity remained high for studies evaluating postcardiotomy cardiogenic shock (I 2 =93%), and mixed shock causes (I 2 =70%), but there was no between-study heterogeneity detected for studies evaluating cardiogenic shock from AMI (I 2 =0%). Evidence of publication bias persisted in studies evaluating postcardiotomy cardiogenic shock. However, there was no evidence of bias for studies evaluating VA-ECMO and IABP in patients with AMI ( Figure 3 ).
In patients with cardiogenic shock complicating AMI, the use of IABP concomitantly with VA-ECMO was associated with lower mortality (50.8% versus 62.4%; RR, 0.56; 95% CI, 0.46-0.67; P<0.001). In patients with postcardiotomy cardiogenic shock (RR, 0.34; 95% CI, 0.06-1.90; P=0. 22 ) and mixed/other causes (RR, 1.23; 95% CI, 0.71-2.13; P=0.47) of cardiogenic shock, there was no difference in mortality in the cohorts with and without IABP use in addition to VA-ECMO.
DISCUSSION
In this large meta-analysis of 4653 patients treated with VA-ECMO for cardiogenic shock, IABP was used in nearly 44% of the patients. The use of concomitant IABP did not influence short-term mortality in the total cohort. In patients with cardiogenic shock complicating AMI, IABP in combination with VA-ECMO was associated with 18.5% lesser mortality as compared to patients only on VA-ECMO.
Short-Term MCS in Cardiogenic Shock
Despite the theoretical advantage of MCS devices in cardiogenic shock, there is limited high-quality evidence supporting their use. 3 In 2012, a large randomized trial showed no benefit of the IABP in cardiogenic shock complicating AMI. 3 This has resulted in the gradual decline in IABP use in clinical practice in the United States; however, it still remains the predominant device of choice in cardiogenic shock patients. 3, 33 Recent large-scale data has demonstrated an increasing trend of VA-ECMO use in the management of medical and surgical cardiogenic shock. 33, 34 Consistent with this literature, our study confirms the trend towards greater VA-ECMO use in cardiogenic shock, with 21 of the 22 studies published within the past 8 years. The VA-ECMO has multiple theoretical advantages in cardiogenic shock that include rapid bedside access with/without fluoroscopy, high cardiac output support of 3 to 5 L, ability to support both cardiac and pulmonary function, and relatively lower patient costs. 6 In addition, VA-ECMO is often used as an adjunct in cardiopulmonary resuscitation and highrisk coronary interventions, making it an attractive first choice in refractory cardiogenic shock. 5 However, in the setting of decreased LV contractility in cardiogenic shock, VA-ECMO causes an additional increase in afterload that can result in worsening LV performance, increasing pulmonary congestion, and an increased need for vasoactive medications. 
27
Concomitant IABP in VA-ECMO
The rationale for IABP as a concomitant MCS device in cardiogenic shock requiring VA-ECMO is multifold. First, the IABP offers the theoretical advantage of unloading the LV to prevent worsening myocardial function, decreasing myocardial oxygen demand, preventing hydrostatic pulmonary edema, and enhancing circulatory support in patients with VA-ECMO. 9, 27 Importantly, the ability of the IABP to improve coronary artery perfusion pressure in diastole is of incremental benefit. In addition to the noted differences in heterogeneity of selected studies, it is possible that this behavior of the IABP in diastole is associated with improvements in outcomes in patients with AMI as compared to the other cohorts. Second, percutaneous MCS, such as the Impella, have not shown convincing outcome benefits over the IABP, potentially resulting in the selection of the IABP as the second MCS device of choice. 35 Furthermore, the costs and complications of percutaneous MCS devices are significantly higher than the IABP that might limit their utility in clinical practice. 35 Third, the decrease in hydrostatic pulmonary edema with the use of IABP in patients on both central and peripheral VA-ECMO could likely aid in earlier extubation and rehabilitation, making this an attractive choice. 27 Despite established data on the hemodynamics of the IABP in patients with cardiogenic shock, there are limited data on the changes in hemodynamic parameters, extent and duration of vasoactive medication use and ventilator use, and duration in patients with cardiogenic shock needing VA-ECMO and IABP. In the study by Bréchot et al, 27 the use of an IABP was associated with shorter ventilation duration (0.7±2.0 versus 2.2±4.3 days; P<0.001). Further data on the hemodynamic and ventilator end points are worthy of further study and may provide feasible alternate end points.
The results of the AMI subgroup of study are in contrast to a prior published meta-analysis. 8 This is likely because of increase in the volume of subsequent publications as evidenced by nearly 307% increase in overall sample size and 704% in the AMI sample size in this study. In addition, improvements in delivery of critical care cardiology and cardiogenic shock care could have likely influenced the results of this meta-analysis; however, this could not be quantified in this study. 2 Importantly, despite the lack of benefit shown by the isolated use of IABP in cardiogenic shock complicating AMI, the early and high cardiac output support with 2 MCS devices likely results in lesser multiorgan dysfunction. 3, 36 Crucially, the timing of IABP and VA-ECMO are important because earlier unloading of the LV before development of vasoplegia and multiorgan failure has important prognostic implications. 36 In the study by Aso et al, 9 the use of concomitant IABP in patients without the need for renal replacement therapy than those with showed greater mortality benefit, highlighting the importance of early MCS use.
The need for dual MCS support needs to be carefully balanced against the potentially increased risk of complications. Despite its stated benefits, the VA-ECMO is associated with a significant need for blood transfusions either because of hemorrhage or hemolysis. 37 The need for large bore femoral arterial cannulation is associated with a higher risk of vascular complications, such as retroperitoneal hemorrhage, distal limb ischemia, and arterial laceration. 38 As noted in Table 3 , significant complications of major bleeding, limb ischemia, vascular access complications, and cerebrovascular accidents were reported across the studies. There was limited head-to-head comparison of the 2 strategies, and the safety profile of these devices need careful evaluation to optimize the risk-benefit ratio in this critically ill population.
Limitations
This study has important limitations. The selection of all types of cardiogenic shock can cause significant heterogeneity in the assessment of clinical outcomes. Importantly, cardiogenic shock complicating AMI and cardiac surgery are fundamentally different in their cause, management, and outcomes. 22 Despite wellestablished randomized trial data on the use of IABP in cardiogenic shock, there are limited adequately powered studies evaluating the VA-ECMO with equal rigor.
3 Therefore, our study consisted primarily of observational studies that carry their individual limitations. Observational studies are prone to confounding by indication and heterogeneity. As recommended by the American Heart Association, we sought to minimize bias by employing random-effects model, subgroup analyses, and sensitivity analyses. 39 This meta-analysis was performed at a study-level population and, thus, despite best attempts, pivotal differences in patient characteristics across studies may have contributed to results observed. Importantly, the presence of publication bias in the total cohort could potentially overemphasize the effect size. However, in patients with AMI, the absence of publication bias and low heterogeneity among studies makes this effect more consistent. Detailed baseline data, specifically an evaluation of early revascularization and timing of MCS, were not uniformly reported across studies. 36, 40 Because of its summative nature, this study was unable to discern the sequence of MCS support. As noted in Table 3 , the IABP was used before the VA-ECMO in most of the studies that reported this information. The use of VA-ECMO before the IABP could potentially represent confounding by indication because it is likely that these patients were sicker at baseline. Finally, this study evaluated short-term mortality only with limited insight into longterm survival and functional recovery, both of which remain a challenge in critical care cardiology literature.
Conclusions
In this meta-analysis of 4653 patients with cardiogenic shock requiring VA-ECMO support, the use of an IABP did not influence mortality in the total cohort. In a subgroup analysis of patients with AMI, use of IABP with VA-ECMO was associated with 18.5% lower mortality in comparison to patients on VA-ECMO alone. The observational nature of the included studies needs to be interpreted with caution given the associated selection and publication biases, and need further confirmation in randomized trials. Given the high mortality associated with cardiogenic shock and the relatively large treatment effect noted in this meta-analysis, we are optimistic that future trials will be appropriately powered with moderate-sized randomized trials.
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